JP2006506380A5 - - Google Patents

Download PDF

Info

Publication number: JP2006506380A5
Authority: JP; Japan
Prior art keywords: triazol; benzyl; tetrahydro; bipyridinyl; ylmethyl
Prior art date: 2003-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2004546268A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006506380A (ja

Filing date

2003-10-14

Publication date

2006-11-30

2002-10-25 Priority claimed from GBGB0224919.1A external-priority patent/GB0224919D0/en

2003-10-14 Application filed filed Critical

2006-02-23 Publication of JP2006506380A publication Critical patent/JP2006506380A/ja

2006-11-30 Publication of JP2006506380A5 publication Critical patent/JP2006506380A5/ja

Status Withdrawn legal-status Critical Current

Links

-1 piperidindiyl Chemical group 0.000 claims description 41
150000001875 compounds Chemical class 0.000 claims description 17
125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
FJPGWXXCNWQVFB-SFHVURJKSA-N (2r)-2-[3-methyl-5-(1-pyrimidin-2-ylpiperidin-4-yl)-1,2,4-triazol-4-yl]-2-phenylethanol Chemical compound N1([C@@H](CO)C=2C=CC=CC=2)C(C)=NN=C1C(CC1)CCN1C1=NC=CC=N1 FJPGWXXCNWQVFB-SFHVURJKSA-N 0.000 claims description 2
WADYUFHRPDIVMM-UHFFFAOYSA-N 2-[4-(4-benzyl-5-butyl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrimidine Chemical compound C=1C=CC=CC=1CN1C(CCCC)=NN=C1C(CC1)CCN1C1=NC=CC=N1 WADYUFHRPDIVMM-UHFFFAOYSA-N 0.000 claims description 2
HWMADBAPMLYUFG-UHFFFAOYSA-N 2-[4-(4-benzyl-5-cyclopropyl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrimidine Chemical compound C1CC1C1=NN=C(C2CCN(CC2)C=2N=CC=CN=2)N1CC1=CC=CC=C1 HWMADBAPMLYUFG-UHFFFAOYSA-N 0.000 claims description 2
QCXGWFGGXDYTGG-UHFFFAOYSA-N 2-[4-(4-benzyl-5-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-4-methylpyrimidine Chemical compound C=1C=CC=CC=1CN1C(C)=NN=C1C(CC1)CCN1C1=NC=CC(C)=N1 QCXGWFGGXDYTGG-UHFFFAOYSA-N 0.000 claims description 2
XUONHDZGZNJKLO-UHFFFAOYSA-N 2-[4-(4-benzyl-5-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrazine Chemical compound C=1C=CC=CC=1CN1C(C)=NN=C1C(CC1)CCN1C1=CN=CC=N1 XUONHDZGZNJKLO-UHFFFAOYSA-N 0.000 claims description 2
VJXCWKBQOICZOM-UHFFFAOYSA-N 2-[4-(4-benzyl-5-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrimidine Chemical compound C=1C=CC=CC=1CN1C(C)=NN=C1C(CC1)CCN1C1=NC=CC=N1 VJXCWKBQOICZOM-UHFFFAOYSA-N 0.000 claims description 2
JPUPXLNQXWYZPT-UHFFFAOYSA-N 2-[4-(4-benzyl-5-propan-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrimidine Chemical compound C=1C=CC=CC=1CN1C(C(C)C)=NN=C1C(CC1)CCN1C1=NC=CC=N1 JPUPXLNQXWYZPT-UHFFFAOYSA-N 0.000 claims description 2
MWMWMHKJJNCLBF-UHFFFAOYSA-N 2-[4-(4-benzyl-5-propyl-1,2,4-triazol-3-yl)piperidin-1-yl]pyrimidine Chemical compound C=1C=CC=CC=1CN1C(CCC)=NN=C1C(CC1)CCN1C1=NC=CC=N1 MWMWMHKJJNCLBF-UHFFFAOYSA-N 0.000 claims description 2
KVHBZEFFGFBZPQ-UHFFFAOYSA-N 2-[4-[4-benzyl-5-(2-methylpropyl)-1,2,4-triazol-3-yl]piperidin-1-yl]pyrimidine Chemical compound C=1C=CC=CC=1CN1C(CC(C)C)=NN=C1C(CC1)CCN1C1=NC=CC=N1 KVHBZEFFGFBZPQ-UHFFFAOYSA-N 0.000 claims description 2
BIJLNARERPNZTM-UHFFFAOYSA-N 2-[4-[4-benzyl-5-[(2-chlorophenoxy)methyl]-1,2,4-triazol-3-yl]piperidin-1-yl]pyrimidine Chemical compound ClC1=CC=CC=C1OCC(N1CC=2C=CC=CC=2)=NN=C1C1CCN(C=2N=CC=CN=2)CC1 BIJLNARERPNZTM-UHFFFAOYSA-N 0.000 claims description 2
BRAHJRKYAUITMC-UHFFFAOYSA-N 2-[4-[4-benzyl-5-[(4-fluorophenoxy)methyl]-1,2,4-triazol-3-yl]piperidin-1-yl]pyrimidine Chemical compound C1=CC(F)=CC=C1OCC(N1CC=2C=CC=CC=2)=NN=C1C1CCN(C=2N=CC=CN=2)CC1 BRAHJRKYAUITMC-UHFFFAOYSA-N 0.000 claims description 2
NHCFGMIJJHVBBV-INIZCTEOSA-N 2-[4-[[5-methyl-4-[(1s)-1-phenylethyl]-1,2,4-triazol-3-yl]methyl]piperidin-1-yl]pyrimidine Chemical compound C1([C@H](C)N2C(=NN=C2C)CC2CCN(CC2)C=2N=CC=CN=2)=CC=CC=C1 NHCFGMIJJHVBBV-INIZCTEOSA-N 0.000 claims description 2
BHBAJITZJZIHFJ-UHFFFAOYSA-N 4-(4-benzyl-5-methyl-1,2,4-triazol-3-yl)-1-phenylpiperidine Chemical compound C=1C=CC=CC=1CN1C(C)=NN=C1C(CC1)CCN1C1=CC=CC=C1 BHBAJITZJZIHFJ-UHFFFAOYSA-N 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
125000000623 heterocyclic group Chemical group 0.000 claims 10
125000004076 pyridyl group Chemical group 0.000 claims 6
125000000714 pyrimidinyl group Chemical group 0.000 claims 6
208000005171 Dysmenorrhea Diseases 0.000 claims 5
206010013935 Dysmenorrhoea Diseases 0.000 claims 5
201000010099 disease Diseases 0.000 claims 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
229910052760 oxygen Inorganic materials 0.000 claims 5
239000008194 pharmaceutical composition Substances 0.000 claims 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
229910052799 carbon Inorganic materials 0.000 claims 4
229910052736 halogen Inorganic materials 0.000 claims 4
150000002367 halogens Chemical class 0.000 claims 4
229910052739 hydrogen Inorganic materials 0.000 claims 4
229920006395 saturated elastomer Polymers 0.000 claims 4
125000004434 sulfur atom Chemical group 0.000 claims 4
125000002393 azetidinyl group Chemical group 0.000 claims 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
125000002883 imidazolyl group Chemical group 0.000 claims 3
125000002757 morpholinyl group Chemical group 0.000 claims 3
125000004430 oxygen atom Chemical group O* 0.000 claims 3
125000004193 piperazinyl group Chemical group 0.000 claims 3
125000003386 piperidinyl group Chemical group 0.000 claims 3
125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
208000024827 Alzheimer disease Diseases 0.000 claims 2
208000019901 Anxiety disease Diseases 0.000 claims 2
201000001320 Atherosclerosis Diseases 0.000 claims 2
201000006474 Brain Ischemia Diseases 0.000 claims 2
206010007027 Calculus urinary Diseases 0.000 claims 2
208000024172 Cardiovascular disease Diseases 0.000 claims 2
208000002177 Cataract Diseases 0.000 claims 2
201000009273 Endometriosis Diseases 0.000 claims 2
206010016654 Fibrosis Diseases 0.000 claims 2
208000018522 Gastrointestinal disease Diseases 0.000 claims 2
208000010412 Glaucoma Diseases 0.000 claims 2
206010019280 Heart failures Diseases 0.000 claims 2
206010020772 Hypertension Diseases 0.000 claims 2
206010021036 Hyponatraemia Diseases 0.000 claims 2
208000019693 Lung disease Diseases 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 claims 2
206010029155 Nephropathy toxic Diseases 0.000 claims 2
208000008589 Obesity Diseases 0.000 claims 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
206010030043 Ocular hypertension Diseases 0.000 claims 2
206010030113 Oedema Diseases 0.000 claims 2
206010033314 Ovulation pain Diseases 0.000 claims 2
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 2
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 2
208000006399 Premature Obstetric Labor Diseases 0.000 claims 2
206010036600 Premature labour Diseases 0.000 claims 2
208000001647 Renal Insufficiency Diseases 0.000 claims 2
208000007536 Thrombosis Diseases 0.000 claims 2
206010047700 Vomiting Diseases 0.000 claims 2
208000022531 anorexia Diseases 0.000 claims 2
239000005557 antagonist Substances 0.000 claims 2
208000006673 asthma Diseases 0.000 claims 2
208000035269 cancer or benign tumor Diseases 0.000 claims 2
208000015114 central nervous system disease Diseases 0.000 claims 2
230000007882 cirrhosis Effects 0.000 claims 2
208000019425 cirrhosis of liver Diseases 0.000 claims 2
208000010877 cognitive disease Diseases 0.000 claims 2
206010061428 decreased appetite Diseases 0.000 claims 2
206010012601 diabetes mellitus Diseases 0.000 claims 2
208000010643 digestive system disease Diseases 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
230000004064 dysfunction Effects 0.000 claims 2
208000018685 gastrointestinal system disease Diseases 0.000 claims 2
208000019622 heart disease Diseases 0.000 claims 2
230000009545 invasion Effects 0.000 claims 2
208000028867 ischemia Diseases 0.000 claims 2
125000000842 isoxazolyl group Chemical group 0.000 claims 2
208000017169 kidney disease Diseases 0.000 claims 2
201000006370 kidney failure Diseases 0.000 claims 2
208000020816 lung neoplasm Diseases 0.000 claims 2
208000037841 lung tumor Diseases 0.000 claims 2
201000003152 motion sickness Diseases 0.000 claims 2
208000031225 myocardial ischemia Diseases 0.000 claims 2
230000007694 nephrotoxicity Effects 0.000 claims 2
231100000417 nephrotoxicity Toxicity 0.000 claims 2
125000004433 nitrogen atom Chemical group N* 0.000 claims 2
235000020824 obesity Nutrition 0.000 claims 2
125000002971 oxazolyl group Chemical group 0.000 claims 2
206010036596 premature ejaculation Diseases 0.000 claims 2
208000026440 premature labor Diseases 0.000 claims 2
125000003373 pyrazinyl group Chemical group 0.000 claims 2
125000003226 pyrazolyl group Chemical group 0.000 claims 2
125000002098 pyridazinyl group Chemical group 0.000 claims 2
125000000168 pyrrolyl group Chemical group 0.000 claims 2
150000003839 salts Chemical class 0.000 claims 2
208000019116 sleep disease Diseases 0.000 claims 2
239000012453 solvate Substances 0.000 claims 2
208000020431 spinal cord injury Diseases 0.000 claims 2
125000003831 tetrazolyl group Chemical group 0.000 claims 2
125000000335 thiazolyl group Chemical group 0.000 claims 2
125000004306 triazinyl group Chemical group 0.000 claims 2
125000001425 triazolyl group Chemical group 0.000 claims 2
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
208000019206 urinary tract infection Diseases 0.000 claims 2
208000008281 urolithiasis Diseases 0.000 claims 2
230000008673 vomiting Effects 0.000 claims 2
229940045860 white wax Drugs 0.000 claims 2
HRGHFZCNGXYKSM-UHFFFAOYSA-N 1-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]pyrrolidin-3-ol Chemical compound C1C(O)CCN1CC(N1CC=2C=CC=CC=2)=NN=C1C1CCN(C=2N=CC=CC=2)CC1 HRGHFZCNGXYKSM-UHFFFAOYSA-N 0.000 claims 1
IGYOBUDMQFDOGS-UHFFFAOYSA-N 1-[[4-benzyl-5-(1-pyrimidin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]piperidin-3-ol Chemical compound C1C(O)CCCN1CC(N1CC=2C=CC=CC=2)=NN=C1C1CCN(C=2N=CC=CN=2)CC1 IGYOBUDMQFDOGS-UHFFFAOYSA-N 0.000 claims 1
KEEPLHBLESCVEN-UHFFFAOYSA-N 2-[4-[4-benzyl-5-(morpholin-4-ylmethyl)-1,2,4-triazol-3-yl]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound N#CC1=CC=CN=C1N1CCC(C=2N(C(CN3CCOCC3)=NN=2)CC=2C=CC=CC=2)CC1 KEEPLHBLESCVEN-UHFFFAOYSA-N 0.000 claims 1
JQWMVVHZFVVRGS-UHFFFAOYSA-N 2-[4-[4-benzyl-5-(morpholin-4-ylmethyl)-1,2,4-triazol-3-yl]piperidin-1-yl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1N1CCC(C=2N(C(CN3CCOCC3)=NN=2)CC=2C=CC=CC=2)CC1 JQWMVVHZFVVRGS-UHFFFAOYSA-N 0.000 claims 1
WXOXVAQYBDLSRL-UHFFFAOYSA-N 2-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methoxy]ethanamine Chemical compound C=1C=CC=CC=1CN1C(COCCN)=NN=C1C(CC1)CCN1C1=CC=CC=N1 WXOXVAQYBDLSRL-UHFFFAOYSA-N 0.000 claims 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 1
125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 1
KRMVZBILFSJMNJ-YDULTXHLSA-N 4-[[4-[(1S)-1-phenylethyl]-5-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1,2,4-triazol-3-yl]methyl]morpholine trihydrochloride Chemical compound Cl.Cl.Cl.C1([C@H](C)N2C(=NN=C2CN2CCOCC2)CN2CCN(CC2)C=2N=CC=CC=2)=CC=CC=C1 KRMVZBILFSJMNJ-YDULTXHLSA-N 0.000 claims 1
YENZIHDMDLNUBF-MLQCRBJCSA-N 4-[[4-[(1S)-1-phenylethyl]-5-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]-1,2,4-triazol-3-yl]methyl]morpholine trihydrochloride Chemical compound Cl.Cl.Cl.C1([C@H](C)N2C(=NN=C2CN2CCOCC2)CN2CCN(CC2)C=2N=CC=CN=2)=CC=CC=C1 YENZIHDMDLNUBF-MLQCRBJCSA-N 0.000 claims 1
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
208000028698 Cognitive impairment Diseases 0.000 claims 1
206010012239 Delusion Diseases 0.000 claims 1
208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
206010070531 Foetal growth restriction Diseases 0.000 claims 1
208000021891 Micturition disease Diseases 0.000 claims 1
208000027099 Paranoid disease Diseases 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
DENLVABGJNYKCR-UHFFFAOYSA-N benzyl 4-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]piperazine-1-carboxylate Chemical compound C1CN(CC=2N(C(C3CCN(CC3)C=3N=CC=CC=3)=NN=2)CC=2C=CC=CC=2)CCN1C(=O)OCC1=CC=CC=C1 DENLVABGJNYKCR-UHFFFAOYSA-N 0.000 claims 1
230000003111 delayed effect Effects 0.000 claims 1
231100000868 delusion Toxicity 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
206010013990 dysuria Diseases 0.000 claims 1
208000030941 fetal growth restriction Diseases 0.000 claims 1
210000003754 fetus Anatomy 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 claims 1
230000009593 intrauterine fetal growth Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
PKOMJEPAIAHLHI-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]-2-methoxy-n-methylethanamine Chemical compound C=1C=CC=CC=1CN1C(CN(C)CCOC)=NN=C1C(CC1)CCN1C1=CC=CC=N1 PKOMJEPAIAHLHI-UHFFFAOYSA-N 0.000 claims 1
JCHXIGNAOIHLPB-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]-2-methoxyethanamine Chemical compound C=1C=CC=CC=1CN1C(CNCCOC)=NN=C1C(CC1)CCN1C1=CC=CC=N1 JCHXIGNAOIHLPB-UHFFFAOYSA-N 0.000 claims 1
DRDVROHBUYOVDB-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]-3-methoxy-n-methylpropan-1-amine Chemical compound C=1C=CC=CC=1CN1C(CN(C)CCCOC)=NN=C1C(CC1)CCN1C1=CC=CC=N1 DRDVROHBUYOVDB-UHFFFAOYSA-N 0.000 claims 1
QJZYCUPWKRRMME-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]-3-methoxypropan-1-amine Chemical compound C=1C=CC=CC=1CN1C(CNCCCOC)=NN=C1C(CC1)CCN1C1=CC=CC=N1 QJZYCUPWKRRMME-UHFFFAOYSA-N 0.000 claims 1
LOVSZWVTDDBQLP-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]ethanamine Chemical compound C=1C=CC=CC=1CN1C(CNCC)=NN=C1C(CC1)CCN1C1=CC=CC=N1 LOVSZWVTDDBQLP-UHFFFAOYSA-N 0.000 claims 1
KGEUFRXQLNRTOP-UHFFFAOYSA-N n-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl]methanesulfonamide Chemical compound C=1C=CC=CC=1CN1C(CNS(=O)(=O)C)=NN=C1C(CC1)CCN1C1=CC=CC=N1 KGEUFRXQLNRTOP-UHFFFAOYSA-N 0.000 claims 1
DNTOTJMNUBQSIZ-UHFFFAOYSA-N n-benzyl-2-[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]acetamide Chemical compound C=1C=CC=CC=1CNC(=O)CC(N1CC=2C=CC=CC=2)=NN=C1C(CC1)CCN1C1=CC=CC=N1 DNTOTJMNUBQSIZ-UHFFFAOYSA-N 0.000 claims 1
LEMUDJYKMLDAIV-UHFFFAOYSA-N n-benzyl-2-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methoxy]acetamide Chemical compound C=1C=CC=CC=1CNC(=O)COCC(N1CC=2C=CC=CC=2)=NN=C1C(CC1)CCN1C1=CC=CC=N1 LEMUDJYKMLDAIV-UHFFFAOYSA-N 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
229940127234 oral contraceptive Drugs 0.000 claims 1
239000003539 oral contraceptive agent Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 claims 1
NZYAUFWFKCBCBS-HSZRJFAPSA-N tert-butyl (2r)-2-[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(N1CC=2C=CC=CC=2)=NN=C1C1CCN(C=2N=CC=CC=2)CC1 NZYAUFWFKCBCBS-HSZRJFAPSA-N 0.000 claims 1
HEZYZUKTRFWBDS-UHFFFAOYSA-N tert-butyl 2-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methoxy]acetate Chemical compound C=1C=CC=CC=1CN1C(COCC(=O)OC(C)(C)C)=NN=C1C(CC1)CCN1C1=CC=CC=N1 HEZYZUKTRFWBDS-UHFFFAOYSA-N 0.000 claims 1
WFQQCYBGBXMDMU-UHFFFAOYSA-N tert-butyl 2-[[4-benzyl-5-(1-pyridin-2-ylpiperidin-4-yl)-1,2,4-triazol-3-yl]methyl-methylamino]acetate Chemical compound C=1C=CC=CC=1CN1C(CN(CC(=O)OC(C)(C)C)C)=NN=C1C(CC1)CCN1C1=CC=CC=N1 WFQQCYBGBXMDMU-UHFFFAOYSA-N 0.000 claims 1
125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1

JP2004546268A 2002-10-25 2003-10-14 月経困難症の治療用トリアゾール化合物 Withdrawn JP2006506380A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0224919.1A GB0224919D0 (en)	2002-10-25	2002-10-25	Triazole compounds useful in therapy
PCT/IB2003/004587 WO2004037809A1 (en)	2002-10-25	2003-10-14	Triazole compounds for the treatment of dysmenorrhoea

Publications (2)

Publication Number	Publication Date
JP2006506380A JP2006506380A (ja)	2006-02-23
JP2006506380A5 true JP2006506380A5 (2)	2006-11-30

Family

ID=9946618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2004546268A Withdrawn JP2006506380A (ja)	2002-10-25	2003-10-14	月経困難症の治療用トリアゾール化合物

Country Status (11)

Country	Link
EP (1)	EP1558598B1 (2)
JP (1)	JP2006506380A (2)
AT (1)	ATE367386T1 (2)
AU (1)	AU2003267791A1 (2)
BR (1)	BR0315676A (2)
CA (1)	CA2502932A1 (2)
DE (1)	DE60315062T2 (2)
ES (1)	ES2287508T3 (2)
GB (1)	GB0224919D0 (2)
MX (1)	MXPA05004305A (2)
WO (1)	WO2004037809A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9150567B2 (en)	2009-10-01	2015-10-06	Cymabay Therapeutics, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317227D0 (en) *	2003-07-23	2003-08-27	Pfizer Ltd	Treatment of male sexual dysfunction
KR100750028B1 (ko) *	2003-02-19	2007-08-16	화이자 인코포레이티드	치료에 유용한 트리아졸 화합물
GB0325021D0 (en) *	2003-10-27	2003-12-03	Pfizer Ltd	Therapeutic combinations
US7745630B2 (en)	2003-12-22	2010-06-29	Justin Stephen Bryans	Triazolyl piperidine arginine vasopressin receptor modulators
BRPI0515482A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos e seus usos como agentes terapêuticos
BRPI0515500A (pt) *	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados piridazina para inibição de estearoil-coa-desaturase
MX2007003332A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AP2007004047A0 (en)	2005-01-20	2007-06-30	Pfizer Ltd	Substituted triazole derivatives as oxtocin antagonists
WO2006114706A1 (en) *	2005-04-26	2006-11-02	Pfizer Limited	Triazole derivatives as vasopressin antagonists
CA2608718A1 (en)	2005-05-18	2006-11-23	Pfizer Limited	1, 2, 4-triazole derivatives as vasopressin antagonists
CA2618646A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP1958631A1 (en) *	2007-02-14	2008-08-20	AEterna Zentaris GmbH	Novel triazole derivatives as ligands of G-protein coupled receptors
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009082526A2 (en) *	2007-10-05	2009-07-02	Pharmacopeia, Inc.	Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
JP5847813B2 (ja)	2010-06-23	2016-01-27	シマベイセラピューティクス，インコーポレーテッド	５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
PL3351104T3 (pl)	2010-07-01	2021-06-14	Azevan Pharmaceuticals, Inc.	Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych
US9006450B2 (en) *	2010-07-01	2015-04-14	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical compositions and uses thereof
EP2785690B1 (en) *	2011-12-02	2016-07-13	Boehringer Ingelheim International GmbH	Piperidine derivatives, pharmaceutical compositions and uses thereof
SG10202001065SA (en)	2014-03-28	2020-04-29	Azevan Pharmaceuticals Inc	Compositions and methods for treating neurodegenerative diseases
AU2017305392A1 (en)	2016-08-03	2019-02-21	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
MX2020002762A (es)	2017-09-15	2020-09-17	Azevan Pharmaceuticals Inc	Composiciones y métodos para tratar una lesión cerebral.
US11724997B2 (en)	2018-03-01	2023-08-15	Annapurna Bio, Inc.	Compounds and compositions for treating conditions associated with APJ receptor activity
US12479816B2 (en)	2019-02-08	2025-11-25	University of Pittsburgh—of the Commonwealth System of Higher Education	20-HETE formation inhibitors
WO2022018121A1 (en) *	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
WO2025252661A1 (en) *	2024-06-03	2025-12-11	Immunic Ag	Reducing body weight and/or induction of satiety by triazolo compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE574944C (de) *	1932-02-14	1933-04-21	Schering Kahlbaum Ag	Verfahren zur Darstellung von 3, 4, 5-trisubstituierten 1, 2, 4-Triazolen
WO2001058880A1 (en) *	2000-02-08	2001-08-16	Yamanouchi Pharmaceutical Co., Ltd.	Novel triazole derivatives
SK16242002A3 (sk) *	2000-05-19	2003-04-01	Merck Patent Gmbh	Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje

2002
- 2002-10-25 GB GBGB0224919.1A patent/GB0224919D0/en not_active Ceased
2003
- 2003-10-14 WO PCT/IB2003/004587 patent/WO2004037809A1/en not_active Ceased
- 2003-10-14 JP JP2004546268A patent/JP2006506380A/ja not_active Withdrawn
- 2003-10-14 BR BR0315676-1A patent/BR0315676A/pt not_active IP Right Cessation
- 2003-10-14 CA CA002502932A patent/CA2502932A1/en not_active Abandoned
- 2003-10-14 MX MXPA05004305A patent/MXPA05004305A/es unknown
- 2003-10-14 DE DE60315062T patent/DE60315062T2/de not_active Expired - Fee Related
- 2003-10-14 AT AT03748487T patent/ATE367386T1/de not_active IP Right Cessation
- 2003-10-14 ES ES03748487T patent/ES2287508T3/es not_active Expired - Lifetime
- 2003-10-14 EP EP03748487A patent/EP1558598B1/en not_active Expired - Lifetime
- 2003-10-14 AU AU2003267791A patent/AU2003267791A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9150567B2 (en)	2009-10-01	2015-10-06	Cymabay Therapeutics, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts

Publication	Publication Date	Title
JP2006506380A5 (2)	2006-11-30
JP2014525444A5 (2)	2015-10-29
WO2015008230A1 (en)	2015-01-22	Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2011515462A5 (2)	2012-05-17
JP2008517945A5 (2)	2008-12-04
CN101918395B (zh)	2014-04-16	三唑联噁二唑衍生物
RU2018138047A (ru)	2020-05-12	Гетероциклические вещества - агонисты gpr119
JP2019526615A5 (2)	2020-10-22
JP2007523181A5 (2)	2008-04-10
JP2013507449A5 (2)	2013-11-28
JP2014511869A5 (2)	2015-05-21
JP2008517926A5 (2)	2008-12-04
JP2008536825A5 (2)	2009-05-14
TW201038586A (en)	2010-11-01	Sulfonamide derivatives
JP2007511485A5 (2)	2007-08-09
JP2006500348A5 (2)	2006-10-26
RU2006127572A (ru)	2008-03-27	Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2009525978A5 (2)	2010-03-25
JP2016515606A5 (2)	2017-11-02
CN102361868A (zh)	2012-02-22	作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物
JP2003510359A5 (2)	2007-11-22
JP2006528147A5 (2)	2007-07-19
JP2004502670A5 (2)	2005-02-03
JP2020511452A5 (2)	2022-06-23
JP2007508346A5 (2)	2007-11-22

JP2006506380A5 - - Google Patents

Info

Links

Applications Claiming Priority (2)

Publications (2)

Family

ID=9946618

Family Applications (1)

Country Status (11)

Cited By (1)

Families Citing this family (26)

Family Cites Families (3)

Cited By (1)

Similar Documents